Endocrinology · ACTH-Producing Pancreatic Neuroendocrine Tumor

Treating the Tumor: Surgery, Radiation, and Oncology

At a Glance

Treatment for an ACTH-producing pancreatic neuroendocrine tumor depends on whether it can be completely removed, whether it has spread, its grade, and its receptor status. Surgery may offer cure; advanced disease may require PRRT, chemotherapy, or targeted medicines with close hormone monitoring.

Once your cortisol levels are stabilized and the metabolic shifts are under control, the focus shifts to the root cause: the pancreatic tumor itself. Treating an ACTH-producing pancreatic neuroendocrine tumor (pNET) requires a strategy that balances the need to remove or shrink the tumor with the ongoing risk of a hormone relapse ^[1]^[2]. Your multidisciplinary tumor board will guide this sequence based on your specific case.

Surgery: The Goal of Cure

If your tumor is localized—meaning it has not spread to distant organs—surgical resection (complete removal) is the preferred definitive treatment ^[1]^[3]. Because these tumors can be aggressive, surgeons aim for “negative margins,” meaning no cancer cells are left at the edge of the removed tissue ^[4].

The Outcome: For many appropriately selected patients, a successful surgery leads to a rapid “correction” of hormone levels ^[5].
The Recovery: Because your body has been used to extreme cortisol, you will likely need temporary steroid replacement therapy (like hydrocortisone) after surgery while your natural adrenal function “wakes up” ^[4].

Somatostatin Analogs (SSAs)

If surgery is not immediately possible, or if the tumor has spread, your team may use medications called Somatostatin Analogs (SSAs), such as octreotide or lanreotide ^[6].

How they work: These drugs “dock” onto receptors (specifically SSTR2) on the surface of the tumor cells to slow down their growth ^[7]^[8].
Hormone Control: While SSAs are excellent at slowing tumor growth, they are not always reliable for stopping the production of ACTH ^[3]^[9]. You may still need to continue taking your cortisol-blocking medications even while on an SSA.

PRRT: “Liquid Radiation” and the Risk of Flare

Peptide Receptor Radionuclide Therapy (PRRT) with Lu-177 DOTATATE is a specialized treatment for tumors that show high receptor levels on a DOTATATE scan ^[10]. It delivers targeted radiation directly to the tumor cells.

The Risk of Hormonal Flare: In small case series, a serious but uncommon risk (sometimes cited around 9% in functional NET cohorts) is that PRRT can cause a “hormonal crisis” or “flare” ^[11]. As the radiation kills tumor cells, they can suddenly “leak” a large amount of stored ACTH into your bloodstream.
Symptoms of a Flare: Within days of treatment, you might experience a sudden spike in blood pressure, rapid weight gain (from fluid), or a return of psychiatric symptoms like psychosis ^[12].
The Safety Plan: Because of this risk, patients with ACTH-secreting tumors must be monitored closely at experienced centers, and doctors must have a personalized “rescue” plan (which may include IV medications like etomidate) ready in case of a crisis ^[13]^[12].

Systemic Therapies: Chemotherapy and Targeted Agents

If the tumor is more aggressive or does not have the receptors needed for SSAs or PRRT, other systemic treatments are used:

CAPTEM (Capecitabine and Temozolomide): This is an oral chemotherapy combination sometimes used for well-differentiated pNETs, depending on tumor burden and grade. It is often chosen when a doctor wants to see a shrinkage of the tumor, perhaps to make it easier to remove surgically later ^[14]^[6].
Targeted Therapies: Drugs like everolimus or sunitinib work by blocking the specific pathways the tumor uses to grow and create new blood vessels ^[6]^[15].
Platinum-Based Chemotherapy: If your pathology report identifies your tumor as a poorly differentiated NEC (Neuroendocrine Carcinoma), the standard treatment is a more intensive chemotherapy, typically platinum plus etoposide ^[16]^[17]. This type of tumor is fast-growing and requires this specific, aggressive approach.

Summary of Tumor Treatments

Treatment Type	Best Suited For…	Key Consideration
Surgery	Localized or limited spread	Offers potential for cure ^[1]
SSAs	SSTR-positive, slow growth	Good for growth; less reliable for ACTH control ^[3]
PRRT	SSTR-positive, advanced	Risk of dangerous ACTH “flare” ^[12]
CAPTEM	Well-differentiated	Evaluated for shrinking tumor size ^[14]
Platinum Chemo	Poorly differentiated (NEC)	Standard approach for aggressive NEC ^[16]

Your multidisciplinary team will decide the best sequence of these treatments based on your tumor’s “personality”—its grade, its location, and how well your body is currently managing the hormone levels ^[6]^[18].

Common questions in this guide

Can surgery cure an ACTH-producing pancreatic neuroendocrine tumor?

When the tumor is localized and has not spread to distant organs, complete surgical removal is the preferred definitive treatment and may correct excess hormone production. Surgeons aim for clear edges, called negative margins, but whether surgery is appropriate depends on the tumor’s location, grade, spread, and your overall health.

Will I need steroids after surgery for an ACTH-producing tumor?

You may need temporary steroid replacement, such as hydrocortisone, after surgery. Long-term exposure to high cortisol can suppress the adrenal glands, so they may need time to resume normal hormone production. Take replacement steroids exactly as prescribed and do not stop them without medical guidance.

Can PRRT cause an ACTH or cortisol crisis?

PRRT with Lu-177 DOTATATE can rarely trigger a serious hormonal flare when tumor cells release stored ACTH after treatment. Warning signs may include a sudden rise in blood pressure, rapid fluid-related weight gain, or severe psychiatric symptoms. Treatment should be planned at an experienced center with close monitoring and an individualized rescue plan.

Do octreotide or lanreotide stop ACTH production?

Octreotide and lanreotide may slow the growth of tumors with somatostatin receptors, especially SSTR2. They are less reliable for stopping ACTH production, so cortisol-lowering medicines may still be needed while an analog is being used.

What chemotherapy is used for advanced or poorly differentiated pancreatic neuroendocrine tumors?

CAPTEM, a combination of capecitabine and temozolomide, may be considered for some well-differentiated pancreatic neuroendocrine tumors, especially when shrinkage is desired. Everolimus or sunitinib may also be options. Poorly differentiated neuroendocrine carcinoma is typically treated with more intensive platinum-based chemotherapy plus etoposide.

Get notified when new evidence is published on pancreatic ACTH-producing neuroendocrine tumor.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (18)

1
The Clinical Features and Molecular Mechanisms of ACTH-secreting Pancreatic Neuroendocrine Tumors.
Zhang C, Jin J, Xie J, et al.
The Journal of clinical endocrinology and metabolism 2020; (105(11)) doi:10.1210/clinem/dgaa507.
PMID: 32785672
2
Adrenocorticotropic hormone-secreting pancreatic neuroendocrine carcinoma with multiple organ infections and widespread thrombosis: A case report.
Yoshihara A, Nishihama K, Inoue C, et al.
World journal of clinical cases 2022; (10(17)):5723-5731 doi:10.12998/wjcc.v10.i17.5723.
PMID: 35979125
3
A Rare Case of Metastatic Adrenocorticotrophic Hormone - Secreting Pancreatic Neuroendocrine Tumor Causing Ectopic Cushing Syndrome in a 46-Year-Old Woman.
Huang JY, Cherayil NA, Boyd P, et al.
The American journal of case reports 2025; (26()):e945653 doi:10.12659/AJCR.945653.
PMID: 40176331
4
Pancreatic ACTH Hypersecretion and Pituitary Macroadenoma.
Bettale CM, Allen JW, Mahdi ZK, Ioachimescu AG
JCEM case reports 2023; (1(1)):luad007 doi:10.1210/jcemcr/luad007.
PMID: 37908262
5
Adrenocorticotropin Hormone Secreting Carcinoma of the Pancreas: A Case Report.
Bleicher J, Lombardo S, Carbine S, et al.
Journal of pancreatic cancer 2019; (5(1)):22-25 doi:10.1089/pancan.2019.0004.
PMID: 31236541
6
Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
Del Rivero J, Perez K, Kennedy EB, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023; (41(32)):5049-5067 doi:10.1200/JCO.23.01529.
PMID: 37774329
7
Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors < 2 Centimeters.
Faggiano A, Modica R, Lo Calzo F, et al.
The Journal of clinical endocrinology and metabolism 2020; (105(1)) doi:10.1210/clinem/dgz007.
PMID: 31586182
8
Pasireotide in the treatment of neuroendocrine tumors: a review of the literature.
Vitale G, Dicitore A, Sciammarella C, et al.
Endocrine-related cancer 2018; (25(6)):R351-R364 doi:10.1530/ERC-18-0010.
PMID: 29643113
9
Case Report: Ectopic Cushing's syndrome caused by a pancreatic neuroendocrine tumor managed through dual steroidogenesis inhibition and endoscopic ultrasound-guided ethanol ablation.
Krzystek Ł, Sagan KP, Andrysiak-Mamos E, et al.
Frontiers in endocrinology 2025; (16()):1700273 doi:10.3389/fendo.2025.1700273.
PMID: 41488150
10
[Importance of peptide receptor radionuclide therapy for the management of neuroendocrine tumours].
Ciuciulkaite I, Herrmann K, Lahner H
Radiologie (Heidelberg, Germany) 2025; (65(5)):371-380 doi:10.1007/s00117-025-01452-y.
PMID: 40227439
11
Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors.
Zandee WT, Brabander T, Blažević A, et al.
The Journal of clinical endocrinology and metabolism 2019; (104(4)):1336-1344 doi:10.1210/jc.2018-01991.
PMID: 30566620
12
Peptide Receptor Radionuclide Therapy-Induced Hypercortisolemic Crisis in Ectopic Cushing Syndrome.
Pandit R, Yamichannaiah C, Lila AR, et al.
JCEM case reports 2025; (3(11)):luaf226 doi:10.1210/jcemcr/luaf226.
PMID: 41035789
13
AIMN, ITANET, SIE joint position paper for the recognition, prevention and management of NET carcinoid syndrome and crises during peptide receptor radionuclide therapy.
Laudicella R, Faggiano A, Pirro V, et al.
European journal of nuclear medicine and molecular imaging 2026; (53(3)):1445-1457 doi:10.1007/s00259-025-07596-2.
PMID: 41055768
14
Peptide Receptor Radionuclide Therapy versus Capecitabine/Temozolomide for the Treatment of Metastatic Pancreatic Neuroendocrine Tumors.
Gujarathi R, Tobias J, Abou Azar S, et al.
Cancers 2024; (16(17)) doi:10.3390/cancers16172993.
PMID: 39272851
15
Advanced Pancreatic Neuroendocrine Neoplasms: Which Systemic Treatment Should I Start With?
Rodriguez-Freixinos V, Thawer A, Capdevila J, et al.
Current oncology reports 2021; (23(7)):80 doi:10.1007/s11912-021-01071-5.
PMID: 33937962
16
An Overview of Altered Pathways Associated with Sensitivity to Platinum-Based Chemotherapy in Neuroendocrine Tumors: Strengths and Prospects.
Stefàno E, De Castro F, Ciccarese A, et al.
International journal of molecular sciences 2024; (25(16)) doi:10.3390/ijms25168568.
PMID: 39201255
17
Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study.
Hijioka S, Hosoda W, Matsuo K, et al.
Clinical cancer research : an official journal of the American Association for Cancer Research 2017; (23(16)):4625-4632 doi:10.1158/1078-0432.CCR-16-3135.
PMID: 28455360
18
European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours.
Kos-Kudła B, Castaño JP, Denecke T, et al.
Journal of neuroendocrinology 2023; (35(12)):e13343 doi:10.1111/jne.13343.
PMID: 37877341

This page is for informational purposes only and does not constitute medical advice. Your endocrinology, oncology, and surgical team should tailor treatment and any hormonal-crisis safety plan to your tumor and current health.